Lung Cancer

I've mentioned in posts in the past about the settings in which local therapy might be appropriate for someone even when we know the cancer is advanced/metastatic.  Here's a brief video that discusses some of these issues, including a situation in which the local treatment isn't specifically aimed at addressing a symptom, as is the usual reason for treating with local therapy for metastatic cancer, but is rather what I'd consider the "Get the Lead Runner" strategy:

[powerpress]

I'm interested in your thoughts.

Here's a brief video I did for Swedish Cancer Institute that explains the basic concepts of maintenance therapy for advanced NSCLC.

I hope it's helpful to those of you just learning about what might come after first line therapy for advanced NSCLC.

There's been a theme with the inhibitors of the epidermal growth factor receptor (EGFR) -- both oral tyrosine kinase inhibitors (TKIs) and IV monoclonal antibodies -- that the patients who demonstrate good results with these agents tend to get a rash, while the patients who don't get a rash do poorly.

Here's a brief video just discussing the rationale for why a systemic treatment like chemotherapy is recommended not only as the cornerstone of treatment for advanced lung cancers, which makes intuitive sense, but also for the majority of patients with earlier stages of lung cancer as well.

[powerpress]

I hope it's helpful.

Here's a brief video on the basic premise of treating locally advanced non-small cell lung cancer. 

[powerpress]

I'll plan to do others in which I'll cover more details on it.  And if you've got video topics for me to cover, just offer your suggestions. 

I would like to share with all of you an article on one of my patients that was featured in the November 2012 issue of Ladies Home Journal.  

The next live webinar to be done through the partnership of GRACE and LUNGevity Foundation will be on the timely subject of using molecular features of a resected non-small cell lung cancer in order to better understand the probability of the cancer recurring. This will be on November 14th, 7 PM Eastern/4 PM Pacific, and will hope to answer the question, "Could these molecular features improve upon current staging efforts to help us refine our recommendations of which patients should receive post-operative chemotherapy in order to reduce the chance of recurrence?"

Here's the second half of the presentation by Dr. Gerard Silvestri, expert pulmonologist and critical care specialist at the Medical University of South Carolina in Charleston, on pulmonary complications from lung cancer treatment.

I would like to share with all of you an article on one of my patients that was featured in Ladies Home Journal. I think her story will resonate with all of you.